The Million Veteran Program (MVP) was established in 2011 as a national research initiative to determine how genetic variation influences the health of US military veterans. Here we genotyped 312,571 MVP participants using a custom biobank array and linked the genetic data to laboratory and clinical phenotypes extracted from electronic health records covering a median of 10.0 years of follow-up. Among 297,626 veterans with at least one blood lipid measurement, including 57,332 black and 24,743 Hispanic participants, we tested up to around 32 million variants for association with lipid levels and identified 118 novel genome-wide significant loci after meta-analysis with data from the Global Lipids Genetics Consortium (total n > 600,000) . Through a focus on mutations predicted to result in a loss of gene function and a phenome-wide association study, we propose novel indications for pharmaceutical inhibitors targeting PCSK9 (abdominal aortic aneurysm), ANGPTL4 (type 2 diabetes) and PDE3B (triglycerides and coronary disease).
L arge-scale biobanks offer the potential to link genes to health traits documented in electronic health records (EHR) with unprecedented power 1 . In turn, these discoveries are expected to improve our understanding of the etiology of common and complex diseases as well as our ability to treat and prevent these conditions. To this end, the MVP was established in 2011 by the Veteran Affairs Office of Research and Development as a nationwide research program within the Veteran Affairs healthcare system 2 . The overarching goal of MVP is to find new biologic insights and clinical associations broadly relevant to human health and to enhance the care of veterans (former US military personnel) through precision medicine.
Blood concentrations of low-density lipoprotein cholesterol (LDL-C), triglycerides, total cholesterol and high-density lipoprotein cholesterol (HDL-C) are heritable risk factors for atherosclerotic cardiovascular disease 3 , a highly prevalent condition among US veterans. Genome-wide association studies (GWAS) to date have identified at least 268 loci that influence these levels [4] [5] [6] [7] [8] [9] [10] [11] [12] , many of which are under investigation as potential therapeutic targets 13, 14 . However, off-target effects have dampened enthusiasm for some of these molecules 15, 16 . Understanding the full spectrum of clinical consequences of a genetic variant through phenome-wide association studies (PheWAS 17 ) may shed light on potential unintended effects as well as novel therapeutic indications for some of these molecules.
We first performed a GWAS including a discovery phase in MVP and a replication phase in the Global Lipids Genetics Consortium (GLGC) (Fig. 1 ). In the discovery phase (stage 1), we performed association testing among 297,626 white (European ancestry), black (African ancestry) and Hispanic MVP participants with blood lipids stratified by ethnicity followed by a meta-analysis of results across all three groups. Replication of MVP findings was conducted in stages 2a or 2b with data from either one of two independent studies from the GLGC. Next, we leveraged the results of our discovery and meta-analysis to (1) estimate the variance explained by known and newly discovered lipid loci; (2) assess the potential of the use of multiple lipid measurements for discovery within MVP;
(3) perform a transcriptome-wide association study (TWAS), a competitive gene-set pathway analysis and a tissue-expression analysis. We then focused on novel, genome-wide lipid-associated, low-frequency missense variants unique to our non-European populations as well as predicted loss of gene function (pLOF) mutations across all ethnic groups, as these associations have identified target pathways for pharmacological inactivation and modulation of cardiovascular risk 14, 18, 19 . Lastly, we performed a PheWAS for a set of DNA sequence variants within genes that have already emerged as therapeutic targets for lipid modulation, leveraging the full catalog of International Classification of Disease, ninth edition (ICD-9) diagnosis codes in the Veteran Affairs EHR to better understand the potential consequences of pharmacological modulation of these genes or their products. We followed up significant findings from our PheWAS with multivariate Mendelian randomization analyses.
Results
Demographics of genotyped MVP participants. A total of 353,323 veterans had genetic data available in MVP, with clinical phenotypes recorded in the Veteran Affairs EHR for over 3,088,030 patient-years prior to enrollment (median of 10.0 years per participant) and 61,747,974 distinct clinical encounters (median of 99 per participant). We categorized veterans into three mutually exclusive ancestral groups for association analysis: (1) non-Hispanic white, (2) non-Hispanic black and (3) Hispanic participants. Admixture plots depicting the genetic background of the black and Hispanic groups are shown in Supplementary Figs. 1 and 2 . Demographics and participant counts for a number of cardiometabolic traits for the 312,571 white, black and Hispanic MVP participants that passed our quality control are depicted in Table 1 .
A subset of 297,626 participants passing quality control had at least one laboratory measurement of blood lipids in their EHR. These individuals collectively had a total of 15,456,328 laboratory entries for blood lipids, or a median of 12 measurements per lipid fraction per participant. To minimize potential confounding from the use of lipid-altering agents with variable adherence, we selected a participant's maximum LDL-C, triglycerides and total cholesterol as well as his or her minimum HDL-C for genetic association analysis 20 . Table 2 summarizes characteristics at enrollment and the distribution lipid levels for MVP participants included in our analysis. As expected, most of the participants were male and 28% were of non-European ancestry. While approximately 45% of participants had evidence of a statin prescription at the time of enrollment, only 8-9% participants had such evidence at the time of their maximum LDL-C or total cholesterol measurement used for our GWAS analysis.
Lipid genetic association and conditional analyses. We successfully imputed (INFO > 0.3, minor allele frequency (MAF) > 0.0003) 19.3, 31.4, and 30.4 million variants for white, black and Hispanic veterans, respectively, using the 1000 Genomes Project 21 reference panel ( Table 2 ). Black and Hispanic participants had substantially more variants available for analysis, reflecting the known greater genetic diversity within these populations 21, 22 . We also identified 6,657 pLOF variants in 4,294 genes across the three ethnicities ( Supplementary Fig. 3 ).
We compared the Z scores and effect estimates from the published literature with those observed in MVP for 444 previously reported 11 exome-wide significant variants for lipids. We found a strong correlation of genetic associations across all four traits, validating the lipid data obtained from the EHR (Supplementary Figs. 4, 5) .
We performed association testing separately among individuals of each of three ancestries (white, black, and Hispanic) in our initial discovery analysis and then meta-analyzed results across ancestry groups using an inverse-variance-weighted fixed-effects method ( Fig. 1a, Supplementary Fig. 6 ). Following trans-ethnic meta-analysis in the discovery phase of our study (stage 1), a total of 46,526 variants at 188 of the 268 known loci for lipids met the genome-wide significance threshold (P < 5 × 10 −8 ) ( Supplementary  Tables 1-4 ). We performed pairwise comparisons of the allele frequencies and effect estimates between white and black participants as well as between white and Hispanic participants for 354 of the 444 previously established independent variants for lipids that were well-imputed in all three ancestral groups in MVP 11 (Fig. 2 ). We observed a much stronger correlation for effect allele frequencies between white and Hispanic participants (Pearson's correlation coefficient R = 0.96) than between white and black participants (R = 0.72), likely reflecting the greater European admixture in the MVP Hispanic participants. The effect estimates among the three ethnicities varied by lipid trait (Fig. 2, Supplementary Fig. 7 ).
We sought replication for variants within MVP with suggestive associations (P < 1 × 10 −4 ) in either stages 2a or 2b (Fig. 1b ). We first attempted replication of these variants using summary statistics from the 2017 GLGC exome array meta-analysis (stage 2a) 11 . If association statistics for promising DNA sequence variants from stage 1 were not available for replication in the 2017 exome arrayfocused study, we sought replication of these variants in publicly Black Fig. 1 | GWAS study design. a, DNA sequence variants across three separate ancestry groups in the MVP were meta-analyzed using an inverse-variance-weighted fixed-effects method in the discovery phase (stage 1). Variants with suggestive association were then brought forward for independent replication. b, DNA sequence variants with suggestive associations (two-sided linear regression P < 1 × 10 −4 ) in the discovery analysis (stage 1) were brought forward for independent replication and tested using summary statistics from the 2017 exome-array-focused GLGC meta-analysis (stage 2a). Only variants with suggestive associations in stage 1 that were not present in the GLGC 2017 exome-array study (stage 2a) were alternatively replicated in the 2013 GLGC joint meta-analysis (stage 2b).
available summary statistics from the 2013 GLGC 'joint metaanalysis' (stage 2b). We did not attempt replication of any variant in both studies given the substantial overlap of participants in these two studies. A total of 170,925 variants demonstrated suggestive association (P < 10 −4 ) in the MVP discovery analysis. Among these variants, 39,663 were also available for in silico replication in either stage 2a (GLGC 2017) or stage 2b (GLGC 2013). We defined significant novel associations as those that were at least nominally significant in replication (P < 0.05) with consistent direction of effect and had an overall P < 5 × 10 −8 (genome-wide significance) in the discovery and replication cohorts combined. Following replication, 118 novel loci (from 141 lead variants) exceeded genome-wide significance (P < 5 × 10 −8 , Supplementary Tables 5-8 ). MAFs of lead variants ranged from 0.08% to 49.9%, with effect sizes ranging from 0.01 to 0.243 standard deviations (σ). For example, carriers of a rare missense mutation in the gene encoding sorting nexin 8 (SNX8 Ile414Thr, (rs144787122, NC_000007.13: 2296552A> G) MAF = 0.35% in MVP) demonstrated a 0.10σ (3.8 mg dl −1 ) higher plasma LDL-C after testing in 587,481 individuals. More than one variant may independently affect plasma lipid levels at any given genetic locus. We performed a conditional analysis using combined summary statistics from MVP and publicly available data from GLGC for each lipid trait ( Supplementary  Fig. 8 ) and identified a total of 826 independently associated lipid variants across 118 novel and 268 previously identified loci (Supplementary Table 9 ).
Variance explained obtained from multiple lipid measurements. The previously mapped 444 lipid variants explain about 7.5-10.5% of the phenotypic variance in lipid levels in the MVP population. The 118 novel loci in our study explain an additional 0.38-0.74% in phenotypic variance, and the 826 independent variants identified in our conditional analysis increase the overall explained phenotypic variance to 8.8-12.3% (Supplementary Table 10 ).
We subsequently explored the impact of multiple lipid measurements in an analysis restricted to 171,314 European MVP participants with ≥ 5 lipid measurements in their EHR. We constructed a weighted genetic risk score (GRS) of 223 variants across 268 of the previously mapped loci with effect estimates available in the 2017 GLGC exome array analysis summary statistics 11 ( Supplementary Table 11 ). Generally across the four lipid traits, the GRS explained a larger proportion of the phenotypic variance with an increasing number of lipid measurements included in the analysis ( Supplementary Table 12 ). In addition, when the maximum/minimum lipid values were used as in our discovery GWAS, the GRS explained more total variance than when using up to five lipid measurements for the LDL-C, triglycerides and total cholesterol phenotypes.
Transcriptome-wide association study. We next performed a TWAS 23 using: (1) pre-computed weights from expression array data measured in peripheral blood from 1,245 unrelated control individuals from The Netherlands Twin Registry 24 , RNA-sequencing data measured in adipose tissue from 563 control individuals from the Metabolic Syndrome in Men study 23 and RNA-sequencing data from post-mortem liver (97 individuals) and tibial artery (285 individuals) tissue from the Genotype-Tissue Expression project 25 (GTEx V6); and (2) combined MVP and GLGC summary statistics for each of the four lipid traits. In brief, this approach integrates information from expression reference panels (variant-expression correlation), GWAS summary statistics (variant-trait correlation), and linkage disequilibrium (LD) reference panels (variant-variant correlation) to assess the association between the cis-genetic component of expression and phenotype 23 . The results yield candidate causal genes from the GWAS results under the assumption that the causal mechanism of the tested genes involves changes in cis-expression. Our TWAS identified a total of 655 genome-wide significant (P < 5 × 10 −8 ) gene-lipid associations (summed across expression reference panels) in 333 distinct genes, including 194 that were significant in more than one tissue or lipid trait (Supplementary  Tables 13-16 , Supplementary Figs. 9-10). The 333 distinct genes fell within 122 genomic loci, 117 of which were within a lipid GWAS region (± 1 Mb around a mapped sentinel GWAS variant) identified in either a prior analysis or in the current study. However, five genes identified by TWAS fell outside of previously mapped GWAS regions, representing potentially novel genomic loci for lipids ( Supplementary Table 17 ). Previous work has suggested that future lipid GWAS with larger sample sizes will likely confirm the novel lipid loci identified by our TWAS 26 . Results from additional competitive gene-set pathway and tissue expression analyses are available in the Supplementary Note.
Non-European low-frequency missense variant associations.
We next focused on ancestry specific low-frequency (MAF < 5%) missense variants, as these variants have been suggested to have a higher likelihood of causality 27, 28 . We identified several novel lowfrequency missense variants associated with one or more lipid levels at genome-wide significance that were specific to black or Hispanic participants. We found a total of five variants associated with LDL-C and/or total cholesterol among black individuals ( Supplementary  Table 18 ) and two associated with HDL-C and/or total cholesterol among Hispanic individuals ( Supplementary Table 19 ) in PCSK9, LDLR, APOB and ABCA1. All ten associations were directionally consistent with the 2017 GLGC exome chip meta-analysis with nine reaching nominal significance (P < 0.05) among 17,009 black and 5,084 Hispanic individuals included in the GLGC study. In addition, the seven variants that we identified were either monomorphic or had a MAF < 0.0005 in the approximately 215,000 white veterans in MVP. Of note, we observed the low-frequency 443Thr allele in PCSK9 within Hispanic individuals to be eightfold more common in black individuals (MAF = 0.011 in Hispanic versus 0.092 in black individuals). We also found that this variant was associated with total cholesterol in black individuals at genome-wide significance.
Predicted loss of gene function lipid associations.
We focused next on the subset of genotyped or imputed pLOF variants (variants that were annotated as premature stop (nonsense), canonical splice sites (splice-donor or splice-acceptor) or insertion/deletion variants that shifted frame (frameshift) by the Variant Effect Predictor software 29 ). A total of 15 distinct pLOF variants demonstrated genomewide significant lipid associations across individuals of all three ethnic groups ( Supplementary Table 20 ). We replicated known pLOF associations at PCSK9 19 , APOC3 18 , ANGPTL8 8 , LPL 30 , CD36 31 and HBB 32 , and we observed genome-wide significant associations of comparable magnitude of effect in each of the three ethnic groups for two pLOF variants: a base substitution in APOC3 55+ 1G> A and a mutation in LPL encoding Ser747Ter. We identified one novel pLOF association. Among white MVP participants, carriers of a rare stop-gain mutation in PDE3B (encoding Arg783Ter; carrier frequency of 1 in 625), exhibited 4.72 mg dl −1 (0.41σ) higher blood HDL-C levels (P < 2.8 × 10 −16 ) and 43.3 mg dl −1 (− 0.27σ) lower blood triglyceride levels (P = 7.5 × 10 −8 ). We found this signal to be independent of a previously reported genome-wide significant association in the region involving a common polymorphism, rs1037378 11 (Arg783Ter; conditional analysis P = 6.3 × 10 −16 for HDL-C and P = 8.91 × 10 −8 for triglycerides). We also identified one individual who was homozygous for Arg783Ter. This PDE3B 'human knockout' was in his sixth decade of life and had HDL-C and triglycerides levels of 73 and 56 mg dl −1 , respectively. He was not on lipid-lowering medication and was free of coronary artery disease (CAD). We replicated the triglyceride and HDL-C associations for this pLOF variant in an independent sample of approximately 45,000 participants of the DiscovEHR study ( Fig. 3a,b ).
Loss of PDE3B function and risk of coronary artery disease.
Hypothesizing that mutations that were damaging or causing loss of function in PDE3B could protect against the development of CAD based on their association with lifelong lower levels of triglycerides in blood, we conducted a case-control study of CAD involving five cohorts: MVP, UK Biobank, Myocardial Infarction Genetics Consortium (MIGen), Penn Medicine Biobank (PMBB) and DiscovEHR. For three studies that underwent exome sequencing (MIGen, PMBB and DiscovEHR), we combined pLOF variants with missense variants that were predicted to be damaging or possibly damaging by each of five computer prediction algorithms (LRT score, MutationTaster, PolyPhen-2, HumDiv, PolyPhen-2 HumVar, and SIFT) as performed previously 30, 33 . Because damaging mutations are individually rare, we aggregated them in subsequent association analysis with CAD ( Supplementary Table 21 ). Among 103,580 individuals with CAD and 566,813 controls available for meta-analysis in these five cohorts, carriers of damaging PDE3B mutations were found to have a 24% decreased risk of CAD (odds ratio, 0.76; 95% confidence interval, 0.65-0.90; P = 0.0015; Fig. 3c ). Data from an additional analysis examining the association of all novel lipid loci identified in our study with CAD are available in the Supplementary Note.
PheWAS of variants in genes targeted by lipid therapies.
We leveraged a median of 65 unique ICD-9 diagnosis codes per participant prior to enrollment in MVP to explore the spectrum of phenotypic consequences of genetic variation within genes targeted by lipid-lowering medicines. We selected five lipid-associated genes currently being targeted by pharmaceutical agents and identified functional variants in these genes: two nonsense variants (LPL Ser474Ter and ANGPTL8 Gln121Ter) and three missense variants (ANGPTL4 Glu40Lys, APOA5 Ser19Trp, PCSK9 Arg46Leu). We considered phenotypes to be significantly associated with a variant if they met a Bonferroni corrected P < 4.98 × 10 −5 (0.05/1,004 traits), a conservative threshold given the correlation structure present among PheWAS phenotypes 34 . Data from a total of 176,913 white veterans were available for analysis after quality control. Among these individuals, we identified 33 statistically significant phenotypic associations across the five variants, all of which are correlated with lipids ( Supplementary  Table 22 ). We replicated known associations with CAD for LPL 30 , ANGPTL4 14 and PCSK9 19 . Notably, carriers of triglyceride-lowering and/or HDL-C-raising mutations in ANGPTL4 (Glu40Lys; 7,013 carriers) were also found to have a reduced risk of type 2 diabetes (Fig. 4) . We replicated the type 2 diabetes association for the ANGPTL4 E40K variant in an independent sample of approximately 452,000 participants in the recently published trans-ethnic diabetes GWAS 35 (odds ratio, 0.89; 95% confidence interval, 0.86-0.93; P = 9.24 × 10 −10 ; Supplementary Fig. 11 ). In addition, carriers of LDL-C-lowering mutations in PCSK9 (Arg46Leu; 5,537 carriers) also demonstrated a reduced risk of abdominal aortic aneurysm (AAA, Fig. 5 ). Lipids and AAA Mendelian randomization analysis. To further explore the causal relationship of lipids on AAA development, we performed a multivariate Mendelian randomization analysis using a weighted GRS of 223 lipid-associated variants and summary data from a GWAS of 5,002 AAA cases and 139,968 controls in MVP. Consistent with our PheWAS results, a 1σ genetically elevated LDL-C was associated with an increased risk of AAA (odds ratio, 1.47; 95% confidence interval, 1.28-1.68; P = 4.4 × 10 −8 ). Furthermore, a 1σ genetically elevated HDL-C level was associated with a decreased risk of AAA (odds ratio, 0.79; 95% confidence interval, 0.68-0.91; P = 0.001); and a 1σ genetically elevated triglyceride level was associated with an increased risk of AAA (odds ratio, 1.40, 95% confidence interval, 1.18-1.66; P = 8.5 × 10 −5 ; Fig. 6 ). An MR-Egger analysis 36 indicated no pleiotropic bias of our lipid genetic instruments (MR-Egger intercept P > 0.05 for all three lipid fractions ( Supplementary Table 23) ).
Disease

Discussion
We leveraged clinical and genetic data from the MVP to investigate the inherited basis of blood lipids in nearly 300,000 US veterans. Our investigation resulted in several key findings. First, we robustly confirmed 188 previously identified loci while concurrently uncovering an additional 118 novel genome-wide significant loci. Next, we identified a total of 826 independent lipid-associated variants increasing the phenotypic variance explained by nearly 2%. We performed a TWAS in four tissues identifying five additional novel lipid loci at a genome-wide level of significance and performed a pathway analysis highlighting lipid transport mechanisms in our GWAS results. We identified ancestry-specific effects of rare coding variation on lipids among white, black and Hispanic participants, and observed 15 pLOF mutations associated with lipids at a genomewide level of significance, including a protein-truncating variant in PDE3B that lowers triglycerides, raises HDL-C and protects against CAD. Finally, we examined the full spectrum of phenotypic consequences for mutations in lipid genes emerging as therapeutic targets, identifying protective effects of functional mutations in PCSK9 for abdominal aortic aneurysm and in ANGPTL4 for type 2 diabetes. We obtained four main insights through our findings. First, we confirm the enormous potential of a large-scale multi-ethnic biobank built within an integrated health-care system in the discovery of the genetic basis of human traits. Specifically, we leveraged the Veteran Affairs' mature nationwide EHR to efficiently extract existing repeated laboratory measures of lipids collected during the course of clinical care in nearly 300,000 veterans over a median of 10 years for GWAS analysis. Our results highlight the expected increase in variance explained by known loci when repeated lipid measurements are considered but also demonstrate the efficiency of examining the single most extreme lipid value least likely influenced by the use of lipid-altering medications. Subsequent meta-analysis (combined n > 600,000) with existing datasets increased the number of known independent genetic lipid loci to nearly 400, including several lipid pathways with links to human disease. For example, common variants near genes such as COL4A2 and ITGA1 identified for LDL-C and/or total cholesterol suggest links to extracellular matrix and cell adhesion biology, two pathways recently implicated by GWAS of CAD 37, 38 . We also demonstrated that carriers of a rare missense mutation in the gene encoding perilipin 1 (PLIN1 Leu90Pro) possess a markedly higher plasma HDL-C (0.243σ). In humans, perilipin 1 is required for lipid-droplet formation, triglyceride storage, as well as free fatty-acid metabolism, and frameshift pLOF mutations in the PLIN1 gene have been reported to result in severe lipodystrophy 39 . A variant downstream of BDNF (encoding brain-derived neurotrophic factor) was found to be associated with HDL-C and triglycerides levels, supporting recent evidence linking this gene with metabolic syndrome and diabetes 40 . These findings not only improve our understanding of the genetic basis of dyslipidemia, but also provide insights into targets for the development of novel therapeutic agents.
Our second insight embraces the benefit of studying individuals with a diverse ethnic background. Such a design can provide valuable incremental information on the nature of previously identified human genetic associations. In MVP, we examined nearly 60,000 black and 25,000 Hispanic veterans for analysis, representing one of the largest single-cohort GWAS to date for these ethnic groups for any trait. Among these individuals, we compared the effect estimates and allele frequencies of lipid-associated variants across ancestral groups and identified seven novel low-frequency coding variants associated with lipids only in non-European populations. Conversely, we also confirmed a shared genetic architecture across all three ethnic groups for pLOF variation at the LPL and APOC3 loci. Previous work identifying low-frequency missense and pLOF variation in lipid genes have led to the development of the next generation of pharmaceutical agents for cardiovascular disease 14, 15, 41, 42 . Expansion of these efforts to larger sample sizes and additional ancestries may help to explain differences in blood lipid levels and risk of atherosclerosis among select populations.
Our third insight centers around our findings for the deleterious exonic variants within PDE3B. These findings lend human genetic support to PDE3B inhibition as a therapeutic strategy for atherosclerosis. Cilostazol, an inhibitor of both the 3A and 3B isoforms of the phosphodiesterase enzyme, is known to have anti-platelet 43 , vasodilatory 44 and inotropic 45 effects through inhibition of PDE3A, and also has well-documented, substantial effects on triglycerides and HDL-C levels 46 -likely through antagonism of PDE3B. We demonstrate that a PDE3B pLOF variant recapitulates the known lipid effects of cilostazol and extend these findings to show that damaging PDE3B mutations are also associated with reduced risk of CAD. Randomized control trials to date have demonstrated the efficacy of cilostazol in intermittent claudication 46 and prevention of restenosis following percutaneous coronary intervention 47 . The drug is also currently used off-label for the prevention of stroke recurrence through a presumed anti-platelet effect 48 . We note that mice genetically deficient in Pde3b display reduced atherosclerosis 49 as well as decreased infarct size and improved cardiac function following experimental coronary artery ligation 50 . In light of our findings, use of cilostazol, or one of its derivatives, for the primary or secondary prevention of CAD deserves further consideration.
Our final insight highlights the potential benefit of PheWAS across a large-scale EHR-based biobank to predict both potentially adverse and beneficial consequences of artificially inhibiting gene function. Here, we provide evidence that pharmacologic PCSK9 inhibition may reduce abdominal aortic aneurysm risk in addition to its known effects on atherosclerotic cardiovascular disease 13 . This finding is further supported by: our Mendelian randomization results; a recently published analysis using an independent AAA dataset 51 ; and a recent report demonstrating that a Pcsk9 gain-offunction mutation augments AAA development in a mouse model 52 . However, we also recognize the possibility that these results may be a consequence of pleiotropic effects induced by a high phenotypic correlation between AAA and the presence of advanced atherosclerotic disease. Thus, additional studies are necessary before definitive conclusions can be made on causality. Similarly, we expand on the potential indications for ANGPTL4 inhibition to include type 2 diabetes. Future PheWAS efforts may identify associations that facilitate prioritization of drugs currently in development, repurposing of therapies already in clinical use, or prediction of adverse or off-target effects prior to investigation through expensive and time-consuming clinical trials.
Several limitations deserve to be mentioned. First, our MVP lipid phenotype definitions are based entirely on EHR data with a high prevalence of use of lipid-lowering therapy at enrollment. We used maximum or minimum values to capture untreated lipid levels, but the possibility of misclassification of lipid levels remains for participants entering the Veteran Affairs healthcare system on therapy. Such misclassification, however, would be expected to generally reduce our power to detect genetic associations. Second, participants in MVP are overwhelmingly male. Although almost 25,000 women were included in our discovery analysis, we did not attempt to detect genetic associations specific to females or heterogeneity of effects between sexes due to suspected limited power. Third, our TWAS identifies candidate causal genes under the assumption that the causal mechanism of the tested genes involves changes in cis-expression. However, we are unable to discriminate between instances of pleiotropy (when a given variant may alter gene expression and affect lipid levels independently) with TWAS alone and further functional analysis may be necessary. Fourth, our analysis demonstrating a lack of association between HDL-C raising alleles and CAD risk may be underpowered given the small number of examined alleles, although this finding has been demonstrated consistently in previous studies 53, 54 . Lastly, power to detect associations for less common diseases in our PheWAS may also be limited despite the overall number of participants included in the analysis.
In conclusion, we identified more than 100 new genetic signals for blood lipid levels utilizing a biobank that exploits existing EHRs of US veterans. We demonstrate the potential of this approach in the discovery of novel genetic associations and the development of novel therapeutic agents. 
Methods
The design of the MVP has been previously described 2 . In brief, individuals aged 19-104 years have been recruited from more than 50 Veterans Affairs Medical Centers nationwide since 2011. Each veteran's EHR data are being integrated into the MVP biorepository, including inpatient ICD-9 diagnosis codes, Current Procedural Terminology procedure codes, clinical laboratory measurements and reports of diagnostic imaging modalities. The MVP received ethical and study protocol approval from the Veteran Affair Central Institutional Review Board in accordance with the principles outlined in the Declaration of Helsinki. Informed consent was obtained from all participants of the MVP study.
Genetic data. DNA extracted from whole blood was genotyped using a customized Affymetrix Axiom biobank array, the MVP 1.0 Genotyping Array. With 723,305 total DNA sequence variants, the array is enriched for both common and rare variants of clinical importance in different ethnic backgrounds. Veterans of three mutually exclusive ethnic groups were identified for analysis: (1) non-Hispanic white veterans (European ancestry), (2) non-Hispanic black veterans (African ancestry) and (3) Hispanic veterans. Further details on the methods used to assign ancestry and perform sample quality control are described in the Supplementary Note.
Variant quality control. Prior to imputation, variants that were poorly called (genotype missingness > 5%) or that deviated from their expected allele frequency based on reference data from the 1000 Genomes Project 21 were excluded. After pre-phasing using EAGLE 55 v.2, genotypes from the 1000 Genomes Project 21 phase 3, v.5 reference panel were imputed into MVP participants via Minimac3 software 56 . Ethnicity-specific principal component analysis was performed using the EIGENSOFT software 57 .
Following imputation, variant-level quality control was performed using the EasyQC R package 58 (see URLs), and the following exclusion metrics were used: ancestry-specific Hardy-Weinberg equilibrium 59 P < 1 × 10 −20 , posterior call probability < 0.9, imputation quality/INFO < 0.3, MAF < 0.0003, call rate < 97.5% for common variants (MAF > 1%) and call rate < 99% for rare variants (MAF < 1%). Variants were also excluded if they deviated by > 10% from their expected allele frequency based on reference data from the 1000 Genomes Project 21 .
EHR-based lipid phenotypes. EHR clinical laboratory data were available for MVP participants from as early as 2003. We extracted the maximum LDL-C, triglycerides and total cholesterol values and minimum HDL-C values for each participant for analysis. These extreme values were selected to approximate plasma lipid concentrations in the absence of lipid-lowering therapy as described previously 20 . For each phenotype (LDL-C, natural log-transformed triglycerides, HDL-C and total cholesterol), residuals were obtained after regressing on age, age 2 , sex and 10 principal components of ancestry. Residuals were subsequently inverse-normal transformed for association analysis. Statin therapy prescription at enrollment was defined as the presence of a statin prescription in the EHR within 90 days before or after enrollment in the MVP. Statin therapy prescription at the maximum lipid measurement was defined as the presence of a statin prescription in the EHR within 90 days prior to the maximum lipid laboratory measurement used in our GWAS analysis. Further details on lipid-phenotype quality control are described in the Supplementary Note.
MVP association analysis.
Genotyped and imputed DNA sequence variants with a MAF > 0.0003 were tested for association with the inverse-normal-transformed residuals of lipid values through linear regression assuming an additive genetic model. In our initial discovery analysis (stage 1), we performed association testing separately among individuals of each of three genetic ancestries (whites, blacks and Hispanics) and then meta-analyzed results across ethnic groups using an inversevariance-weighted fixed-effects method. For variants with suggestive associations (association P < 10 −4 ), we sought replication of our findings in one of two independent studies: the 2017 GLGC exome array meta-analysis 11 (stage 2a) or the 2013 GLGC joint meta-analysis 5 (stage 2b). Replication was first attempted using summary statistics from the 2017 GLGC exome array study (stage 2a). A total of 242,289 variants in up to 319,677 individuals were analyzed after quality control and were available for replication. If a DNA sequence variant was not available for replication in the above exome array-focused study, we sought replication from publicly available summary statistics from the 2013 GLGC joint meta-analysis (stage 2b). An additional 2,044,165 variants in up to 188,587 individuals were available for replication in this study. In total, 2,286,454 DNA sequence variants in up to 319,677 individuals were available for independent replication in either stage 2a or stage 2b. We emphasize that if a variant was available for replication in both studies, replication was performed only using summary statistics from the 2017 GLGC exome array study given its larger sample size. We defined significant novel associations as those that were at least nominally significant in replication (P < 0.05) and had an overall P < 5 × 10 −8 (genome-wide significance) in the discovery and replication cohorts combined. Novel loci were defined as being greater than 1 Mb away from a known genome-wide-associated lead variant for lipids. Additionally, LD information from the 1000 Genomes Project 21 was used to determine independent variants for which a locus extended beyond 1 Mb. All association P values were two-sided. Further details on the association analysis are described in the Supplementary Note.
Conditional analysis.
We used the COJO-GCTA software (see URLs) to perform an approximate, stepwise conditional analysis to identify independent variants within lipid-associated loci given that individual level data for the prior GLGC lipid analyses are not publicly available. We used summary statistics of ~1.9 million overlapping variants that we meta-analyzed across either one of the two GLGC datasets (predominantly European) and the European MVP dataset to conduct this analysis ( Supplementary Fig. 8 ) combined with an LD matrix obtained from 10,000 unrelated European individuals randomly sampled from the UK Biobank interim release.
Variance explained using multiple lipid measurements. We estimated the proportion of variance explained by the set of 444 previously mapped independent lipid variants, the 118 novel lipid loci identified in our study, and the 826 independent lipid variants identified from conditional analysis using ridge regression with the glmnet R package. The variance explained was determined after tuning the hyperparameter (lambda) to approximate an optimal value, and then calculating the model R 2 after performing linear regression with the inversenormal-transformed lipid outcome and each set (444, 118, 826) of independent genome-wide lipid variants as predictors.
We estimated the variance explained for a GRS of 223 previously described GWAS lipid variants weighted by their previously reported effect sizes 11 ( Supplementary Table 11 ) as a function of the number of lipid measurements in MVP to assess the potential impact of using multiple lipid measurements in discovery. We performed this analysis using the mean of one, two, three, four and five lipid measurements for each individual starting with their measurement closest to enrollment and moving towards the past. To account for the use of statin therapy, individuals with evidence of a statin prescription in their EHR at the time of enrollment had their LDL-C and total cholesterol values adjusted by dividing by 0.7 and 0.8, respectively, as previously described 5 . In addition, we also calculated the variance explained by the single maximum triglycerides, LDL-C and/or total cholesterol levels and minimum HDL-C levels from the EHR without adjustment for lipid-lowering therapy. Our analyses were restricted to a subset of 171,314 European MVP participants with ≥ 5 lipid measurements.
Lipid TWAS. We performed a TWAS using summary statistics after a metaanalysis of ~1.9 million overlapping variants among GLGC (predominantly European) and European MVP datasets ( Supplementary Fig. 8 ) and four geneexpression reference panels (whole blood from The Netherlands Twin Registry, adipose tissue from the Metabolic Syndrome in Men study, and tibial artery and liver from GTEx) in independent samples as previously described 23 . In brief, for a given gene, variant-expression weights in the 1-Mb cis locus were first computed with BSLMM 60 , which "models effects on expression as a mixture of normal distributions to account for the sparse expression architecture. Given weights w, lipid Z scores Z, and variant-correlation (LD) matrix D; the association between predicted expression and lipids (that is, the TWAS statistic) was estimated as Z TWAS = w'Z/(w'Dw) 1/2 " (details have been previously described 23 ). We computed TWAS statistics by using either the variants genotyped in each expression reference panel or imputed HapMap3 variants. To account for multiple hypotheses, we applied a genome-wide significant P value threshold (two-sided P < 5 × 10 −8 ), considerably more stringent than previously used Bonferroni corrections in prior TWAS 26 . We defined novel TWAS loci as a TWAS gene falling outside of a previously identified lipid GWAS region (± 1 Mb around a mapped sentinel GWAS variant).
Identification of independent low-frequency coding variant lipid associations specific to blacks and hispanics.
We used the P value and LD-driven clumping procedure in PLINK version 1.90b (--clump) to identify associations between lowfrequency coding variants and lipids specific to black and Hispanic individuals. Input-included summary lipid association statistics from our MVP 1000 Genomes imputed genome-wide association study of black and Hispanic individuals, and reference LD panels of 661 African and 347 admixed American samples from 1000 Genomes phase 3 whole-genome sequencing data. Variants were clumped with stringent r 2 (< 0.01) and P (< 5 × 10 −8 ) thresholds in a 1-Mb region surrounding the lead variant at each locus to reveal independent index variants at genome-wide significance. From this list of independent variants, we report novel proteinaltering variants specific to black and Hispanic individuals at a MAF < 0.05.
Loss of gene function analysis.
We used the Variant Effect Predictor 29 software to identify pLOF DNA sequence variants defined as: premature stop (nonsense), canonical splice-sites (splice-donor or splice-acceptor) or insertion/deletion variants that shifted frame (frameshift). For the pLOF lipids analysis, we then merged these variants with data from the Exome Aggregation Consortium 27 (v.0.3.1, see URLs), a publicly available catalogue of exome-sequence data to confirm consistency in variant annotation. We required that pLOF DNA sequence variants be observed in at least 50 individuals, and set a statistical significance threshold of P < 5 × 10 −8 (genome-wide significance).
Loss of PDE3B gene function and CAD.
We identified a novel lipid association for a pLOF mutation in the PDE3B gene (rs150090666, Arg783Ter). For carriers of damaging mutations in phosphodiesterase 3B, we examined the effects of the mutation on risk for CAD using logistic regression in five separate cohorts: MVP, UK Biobank and three cohorts with exome sequencing: the MIGen, the PMBB and DiscovEHR. In studies with exome sequencing, we combined pLOF variants with missense variants predicted to be damaging or possibly damaging by each of five computer prediction algorithms (LRT score, MutationTaster, PolyPhen-2, HumDiv, PolyPhen-2 HumVar and SIFT) as performed previously 30, 33 . Because any individual damaging mutation was rare, variants were aggregated together for subsequent phenotypic analysis. We performed logistic regression on disease status, adjusting for age, sex and principal components of ancestry as appropriate. Effects of PDE3B damaging mutations were pooled across studies using an inversevariance-weighted fixed-effects meta-analysis. Further details on participating cohorts and CAD case definitions are described in the Supplementary Note. We set a two-sided P < 0.05 threshold for statistical significance.
PheWAS of variation in genes targeted by lipid-lowering therapies.
For a set of DNA sequence variants within genes targeted by lipid-lowering medicines, we performed a PheWAS leveraging the full catalog of EHR ICD-9 diagnosis codes. We selected five lipid genes currently being targeted by pharmaceutical agents and identified functional variants in these genes: two nonsense variants (LPL Ser474Ter and ANGPTL8 Gln121Ter) and three missense variants (ANGPTL4 Glu40Lys, APOA5 Ser19Trp, PCSK9 Arg46Leu). Details on PheWAS quality control, case definitions and association analysis are described in the Supplementary Note. We considered phenotypes to be significantly associated with a variant if they met a Bonferroni corrected two-sided P < 4.98 × 10 −5 (0.05/1,004 traits). For replication of our ANGPTL4 Glu40Lys type 2 diabetes finding, we combined the PheWAS results with publicly available data from the recently published trans-ethnic type 2 diabetes GWAS 35 using an inverse-variance-weighted fixed-effects method.
Lipids and AAA Mendelian randomization analysis. Summary-level data for 223 genome-wide lipid-associated variants were obtained from publicly available data from the Global Lipids Genetics Consortium 11 . We then utilized results from a GWAS of 5,002 AAA cases and 139,968 controls performed in white MVP participants using the previously proposed definition 17 . The effect alleles were matched with all lipid and AAA summary data and three different Mendelian randomization analyses were performed: (1) inverse-variance-weighted; (2) multivariable; and (3) MR-Egger to account for pleiotropic bias. First, we performed inverse-variance-weighted Mendelian randomization using each set of variants for each lipid trait as instrumental variables. This method, however, does not account for possible pleiotropic bias. Therefore, we next performed inverse-variance-weighted multivariable Mendelian randomization. This method adjusts for possible pleiotropic effects across the included lipid traits in our analyses using effect estimates from the variant-AAA outcome and effect estimates from variant-LDL-C, variant-HDL-C and variant-triglycerides as predictors in one multivariable model. We additionally performed MR-Egger as previously described 36 . This technique can be used to detect bias secondary to unbalanced pleiotropy in Mendelian randomization studies. In contrast to inversevariance-weighted analysis, the regression line is unconstrained, and the intercept represents the average pleiotropic effects across all variants. Bonferroni-corrected two-sided P values (P = 0.016 (0.05/3)) for three tests were used to declare statistical significance. 
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For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Our web collection on statistics for biologists may be useful.
Software and code
Policy information about availability of computer code
Data collection
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